Marksans Pharma Limited (NSE: MARKSANS | BSE: 524404), a global pharmaceutical company focused on regulated markets, has entered into a definitive agreement to acquire 100% of the share capital of QliniQ BV, a Netherlands-based pharmaceutical and medical products company with established sales, marketing and distribution operations across the Dutch healthcare sector.
The acquisition represents a significant strategic step in Marksans Pharma’s efforts to strengthen its presence in Europe and expand its market-access capabilities through direct ownership of front-end commercial operations within the European Union. Headquartered in Oldenzaal, QliniQ has built a specialized portfolio of niche prescription medicines and medical devices across therapeutic areas including women’s health, dermatology, respiratory care, endocrinology and gastroenterology. The company operates through multiple channels, including wholesalers, pharmacies, hospitals, insurer-led tenders and direct-to-consumer platforms.
For the financial year ended December 31, 2025, QliniQ reported revenue of €9.35 million and net profit of €1.01 million. The company has demonstrated strong growth over recent years, recording a revenue compound annual growth rate of approximately 41% between FY2023 and FY2025 while maintaining a debt-free balance sheet.
The transaction provides Marksans with immediate access to one of Europe’s key pharmaceutical markets and strengthens its ability to commercialize both existing and future products through established distribution and regulatory infrastructure. The acquisition also brings long-standing relationships with wholesalers, pharmacies, hospitals and health insurers, supporting broader market penetration opportunities.
Commenting on the transaction, Mark Saldanha, Chairman and Managing Director of Marksans Pharma, said, “This acquisition is an important milestone in our strategy to deepen our presence across regulated European markets. QliniQ has built a strong niche portfolio supported by proven market-access capabilities, trusted customer relationships and participation in key healthcare channels. The addition of these capabilities will strengthen our ability to expand our product portfolio and accelerate growth opportunities across Europe.”
Albert de Bruin and Raymond Lansink, Board Members and Shareholders of QliniQ BV, added, “Marksans has established a strong reputation in product development, manufacturing excellence and long-term value creation. We believe the combination of Marksans’ global capabilities and QliniQ’s local market expertise creates a powerful platform for future growth. Together, we share a common objective of improving access to high-quality healthcare solutions while creating value for patients, healthcare professionals, partners and employees.”
Marksans Pharma Limited is a Mumbai-based global pharmaceutical company engaged in the research, development, manufacturing, marketing, and distribution of pharmaceutical formulations. Founded in 1992 and led by its Founder, Chairman and Managing Director, Mark Saldanha, the company has established a strong presence across key international markets, including the United States, the United Kingdom, Europe, Australia, and New Zealand.
Marksans offers a diversified portfolio of generic prescription medicines and over-the-counter (OTC) healthcare products, catering to a wide range of therapeutic segments. The company operates world-class manufacturing facilities that are approved by leading global regulatory authorities, enabling it to serve customers across multiple geographies with high-quality and affordable healthcare solutions.
For the financial year ended March 31, 2026, Marksans Pharma reported consolidated total income of approximately ₹3,033 crore and profit after tax of approximately ₹420 crore, reflecting its consistent growth trajectory and operational strength. The company continues to expand its global footprint through a combination of product innovation, strategic market penetration, and manufacturing excellence.
